These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16786960)

  • 1. [A new step towards an influenza A H5N1 vaccine].
    Nau JY
    Rev Med Suisse; 2006 May; 2(67):1431. PubMed ID: 16786960
    [No Abstract]   [Full Text] [Related]  

  • 2. [New steps towards an influenza A vaccine].
    Nau JY
    Rev Med Suisse; 2006 May; 2(68):1499. PubMed ID: 16783999
    [No Abstract]   [Full Text] [Related]  

  • 3. An inactivated subvirion influenza A (H5N1) vaccine.
    Johansson BE; Brett IC
    N Engl J Med; 2006 Jun; 354(25):2724-5; author reply 2724-5. PubMed ID: 16790710
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An inactivated subvirion influenza A (H5N1) vaccine.
    Focosi D
    N Engl J Med; 2006 Jun; 354(25):2724-5; author reply 2724-5. PubMed ID: 16795150
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine.
    Lin JT; Li CG; Wang X; Su N; Liu Y; Qiu YZ; Yang M; Chen JT; Fang HH; Dong XP; Yin WD; Feng ZJ
    J Infect Dis; 2009 Jan; 199(2):184-7. PubMed ID: 19067606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza vaccine 2007-2008.
    Med Lett Drugs Ther; 2007 Oct; 49(1271):81-3. PubMed ID: 17912142
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
    Goji NA; Nolan C; Hill H; Wolff M; Noah DL; Williams TB; Rowe T; Treanor JJ
    J Infect Dis; 2008 Sep; 198(5):635-41. PubMed ID: 18694338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines against avian influenza--a race against time.
    Poland GA
    N Engl J Med; 2006 Mar; 354(13):1411-3. PubMed ID: 16571885
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children.
    Vajo Z; Kosa L; Szilvasy I; Pauliny Z; Bartha K; Visontay I; Kis A; Tarjan I; Rozsa N; Jankovics I
    Pediatr Infect Dis J; 2008 Dec; 27(12):1052-6. PubMed ID: 18978514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
    Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
    Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets.
    Lipatov AS; Hoffmann E; Salomon R; Yen HL; Webster RG
    J Infect Dis; 2006 Oct; 194(8):1040-3. PubMed ID: 16991078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NEW technologies for meeting the global demand for pandemic influenza vaccines.
    Fedson DS
    Biologicals; 2008 Nov; 36(6):346-9. PubMed ID: 18715803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Registration of the first human vaccine against the highly pathogenic avian influenza A(H5N1) virus: considerations].
    de Jong JC; Osterhaus AD
    Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2113-5. PubMed ID: 18856026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines against influenza A (H5N1): evidence of progress.
    Poland GA; Sambhara S
    J Infect Dis; 2008 Sep; 198(5):629-31. PubMed ID: 18694337
    [No Abstract]   [Full Text] [Related]  

  • 18. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.